GGrantIndex
← Leaderboards

Gary J Nabel

National Institute Of Allergy And Infectious Diseases

$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding mix

By agency

By mechanism

Top collaborators

No co-investigators on record.

Most similar at National Institute Of Allergy And Infectious Diseases

Same institution · by research overlap

Others in their field

Top investigators on “Vaccines

Research focus

VaccinesImmune ResponseProteinsVectorVaccine DevelopmentVirusViral ProteinsHiv-1ViralInfluenzaImmunityAntibodiesAdenovirusesNeutralizing AntibodyT-LymphocyteRecombinantsInfection PreventionNonhuman PrimateInfectionVaccination StrategyHiv InfectionsGenetic VaccinePreventSerotyping

Grant awards (33)

HIV/AIDS Vaccine Development$6,479,015
ZIA · FY2012 · AI · contact PI
Modifications to improve HIV neutralizing antibodies$1,800,000
ZIA · FY2012 · AI · contact PI
Influenza Vaccine Development$1,695,001
ZIA · FY2012 · AI · contact PI
Recombinant Adenovirus Vector Vaccine Studies$1,495,002
ZIA · FY2012 · AI · contact PI
Development of Vaccines for Chikungunya and Other Alphaviruses$678,000
ZIA · FY2012 · AI · contact PI
AAV vectored vaccines$549,483
ZIA · FY2012 · AI · contact PI
Methods for Inhibiting Ebola Virus Replication$240,588
ZIA · FY2012 · AI · contact PI
Mechanisms Of HIV-1 Entry and Transfer to CD4+ T cells$220,670
ZIA · FY2012 · AI · contact PI
HIV/AIDS Vaccine Development$6,779,015
ZIA · FY2011 · AI · contact PI
Recombinant Adenovirus Vector Vaccine Studies$1,695,002
ZIA · FY2011 · AI · contact PI
Influenza Vaccine Development$1,695,001
ZIA · FY2011 · AI · contact PI
Development of Vaccines for Chikungunya and Other Alphaviruses$678,000
ZIA · FY2011 · AI · contact PI
Methods for Inhibiting Ebola Virus Replication$240,588
ZIA · FY2011 · AI · contact PI
Mechanisms Of HIV-1 Entry and Transfer to CD4+ T cells$225,517
ZIA · FY2011 · AI · contact PI
HIV/AIDS Vaccine Development$6,804,629
ZIA · FY2010 · AI · contact PI
Influenza Vaccine Development$1,701,158
ZIA · FY2010 · AI · contact PI
Recombinant Adenovirus Vector Vaccine Studies$1,701,158
ZIA · FY2010 · AI · contact PI
Development of Vaccines for Chikungunya$680,462
ZIA · FY2010 · AI · contact PI
Methods for Inhibiting Ebola Virus Replication$241,409
ZIA · FY2010 · AI · contact PI
Mechanisms Of HIV-1 Entry and Transfer to CD4+ T cells$226,822
ZIA · FY2010 · AI · contact PI
HIV/AIDS Vaccine Development$2,695,631
ZIA · FY2009 · AI · contact PI
The Mechanisms Involved in Ebola Glycoprotein Induced Cytotoxicity$1,475,675
ZIA · FY2009 · AI · contact PI
Influenza Vaccine Development$1,425,675
ZIA · FY2009 · AI · contact PI
Recombinant Adenovirus Vector Vaccine Studies$1,096,350
ZIA · FY2009 · AI · contact PI
Mechanisms Of HIV-1 Entry and Transfer to CD4+ T cells$570,316
ZIA · FY2009 · AI · contact PI
Development of Vaccines for Chikungunya$286,350
ZIA · FY2009 · AI · contact PI
Influenza Vaccine Development$1,489,572
Z01 · FY2008 · AI · contact PI
The Mechanisms Involved in Ebola Glycoprotein Induced Cytotoxicity$1,489,572
Z01 · FY2008 · AI · contact PI
HIV/AIDS Vaccine Development$1,162,466
Z01 · FY2008 · AI · contact PI
Recombinant Adenovirus Vector Vaccine Studies$1,069,851
Z01 · FY2008 · AI · contact PI
Development of Broad-Spectrum Antiviral Agents$839,875
Z01 · FY2008 · AI · contact PI
Mechanisms Of HIV-1 Entry and Transfer to CD4+ T cells via DC-SIGN$592,466
Z01 · FY2008 · AI · contact PI
Development of Vaccines for Chikungunya$271,897
Z01 · FY2008 · AI · contact PI